We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Sponsor content
215 result(s) found, displaying 41 to 50
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Medication transfer set.
-
Prescription medicine registrationActive ingredients: lanadelumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Subcutaneous/intramuscular injection set, medicated.
-
Australian public assessment report (AusPar)Adcetris (brentuximab vedotin) has been approved for the treatment of Hodgkin lymphoma in patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack.